-
Phase 1
-
-
18-65Age Range
-
2Locations
-
Not Yet Recruiting
Not Yet Recruiting
A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
This study will evaluate the effect of inhibitors, at steady state, on the drug levels, safety, and tolerability of BMS-986235 when taken by healthy participants. The inhibitors to be utilized in this study are fluconazole, bupropion, and itraconazole.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - Body mass index of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening. - Males and females must agree to follow specific methods of contraception, if applicable. - Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations, and no significant findings in medical history. Exclusion Criteria: - Women of childbearing potential (WOCBP), women who are pregnant or breastfeeding - Inability to tolerate oral medication - Known previous exposure to BMS-986235. Other protocol-defined inclusion/exclusion criteria apply
Experimental: Arm A: BMS-986235+Fluconazole
Experimental: Arm B: BMS-986235+ Bupropion
Experimental: Arm C: BMS-986235+ Itraconazole